NCT01479075 (Centrin) is a Phase 4 clinical trial of intransal insulin in Diabetes, sponsored by German Diabetes Center.

Who is sponsoring NCT01479075?

NCT01479075 is sponsored by German Diabetes Center.

What drugs are being tested in NCT01479075?

Interventions in NCT01479075: intransal insulin, Placebo, taVNS, sham stimulation.

Is NCT01479075 still recruiting?

NCT01479075 is currently completed. Last updated 2 June 2023.

Last reviewed 2023-06-02 · How we verify

NCT01479075: Centrin

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Central Insulin on Insulin Sensitivity and Energy Metabolism

Completed Phase 4 Last updated 2 June 2023

What this trial tests

Phase 4 trial testing intransal insulin in Diabetes in 30 participants. Completed in 1 June 2014.

Timeline

1 August 2011

Primary endpoint
1 January 2014

1 June 2014

Quick facts

Lead sponsor	German Diabetes Center
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	30
Start date	1 August 2011
Primary completion	1 January 2014
Estimated completion	1 June 2014
Sites	1 location across Germany

Drugs / interventions tested

intransal insulin — full drug profile →
Placebo
taVNS
sham stimulation

Conditions studied

Diabetes — all drugs for Diabetes →

Sponsor

German Diabetes Center — full company profile →

Who can join

Adults 30 to 70, any sex, with Diabetes. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Insulin sensitivity
Time frame: 6 months
Assessment of insulin sensitivity with gold standard methods

Sponsor's own description

Insulin has a direct effect on the energy metabolism of the brain under basal conditions and has an effect on the hepatic glucose production, lipid metabolism and the secretion of various hormone. The effect of intranasal insulin on peripheral metabolism in humans supposedly is mediated by the vagus nerve. The purpose of this study is to determine whether central insulin influences the human peripheral insulin sensitivity of liver and muscle and whether vagus nerve stimulation can mimick this effect.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Shortcut Approaches to Substance Delivery into the Brain Based on Intranasal Administration Using Nanodelivery Strategies for Insulin.
Tashima T. · · 2020 · cited 37× · PMID 33171799 · DOI 10.3390/molecules25215188
Constant hepatic ATP concentrations during prolonged fasting and absence of effects of Cerbomed Nemos<sup>®</sup> on parasympathetic tone and hepatic energy metabolism.
Gancheva S, Bierwagen A, Markgraf DF, Bönhof GJ, et al · · 2018 · cited 19× · PMID 29122559 · DOI 10.1016/j.molmet.2017.10.002

Verify or expand the search:

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Other German Diabetes Center trials

Trials by the same sponsor.

NCT06193668 — Overfeeding Induced Fat-tissue Stimulation · NA · recruiting
NCT04219215 — Acute Hyperbaric Oxygen Treatment Increases Hepatic Insulin Sensitivity and Muscle Reactive Oxygen Species in T2D · NA · completed
NCT04222231 — RESIST! Blood-flow Restriction Resistance Training for Improving Insulin Sensitivity in Type 2 Diabetes · NA · unknown
NCT04088851 — "Hepatic Substrate Flux Rates in Type 2 Diabetes" · NA · active not recruiting
NCT05046483 — Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01479075 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by German Diabetes Center
Last refreshed: 2 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01479075.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing